Clinical Scorecard: A gene expression profile identifies a distinct subtype of Stomach Adenocarcinomas characterized by reduced Claudin levels and an elevated ratio of NF-YA long to NF-YA short splice variants

At a Glance

Key Highlights

• Identification of a Claudinlow STAD subtype characterized by low Claudin expression and a distinct 24-gene transcriptomic signature.
• Elevated NF-YAl/NF-YAs expression ratio correlates with EMT features and poor clinical outcomes in STAD and other epithelial cancers.
• Molecular classifications (TCGA and ACRG) define multiple STAD subtypes, with Claudinlow representing a fifth subgroup linked to EMT.

Guideline-Based Recommendations

Diagnosis

• Utilize gene expression profiling to identify Claudinlow subtype in STAD using 24-gene and 158-gene signatures.
• Apply molecular classification systems (TCGA, ACRG) to stratify STAD tumors into subtypes including Claudinlow.
• Assess NF-YAl/NF-YAs splice variant ratio as a biomarker for EMT phenotype and aggressive tumor behavior.

Management

• Consider molecular subtype information for prognosis and potential therapeutic targeting, especially EMT-associated Claudinlow tumors.
• Investigate targeted therapies addressing EMT features and NF-YA isoform regulation in Claudinlow STAD.

Monitoring & Follow-up

• Monitor gene expression changes in Claudin and NF-YA isoforms to evaluate tumor progression and treatment response.
• Use transcriptomic signatures to predict clinical outcomes and guide personalized treatment strategies.

Risks

• Claudinlow STAD subtype is associated with poor prognosis due to enhanced EMT and metastatic potential.
• High NF-YAl/NF-YAs ratio correlates with aggressive tumor phenotypes and may indicate resistance to conventional therapies.

Patient & Prescribing Data

Patients diagnosed with stomach adenocarcinoma, particularly those classified within Claudinlow and EMT molecular subtypes.

Molecular profiling including NF-YA isoform ratios and Claudin expression may inform prognosis and guide experimental or targeted therapeutic approaches.

Clinical Best Practices

• Incorporate molecular classification and gene expression profiling in routine diagnostic workflows for STAD.
• Evaluate Claudin protein levels and NF-YA splice variant ratios to identify high-risk Claudinlow subtypes.
• Use integrated transcriptomic signatures to refine prognosis and tailor patient management plans.
• Consider research protocols or clinical trials targeting EMT pathways and NF-YA isoform modulation in Claudinlow STAD.

References

• The Cancer Genome Atlas Research Network, 2014
• Asian Cancer Research Group (ACRG) classification
• Nishijima et al. 24-gene Claudinlow signature
• NF-YA isoforms and EMT in epithelial cancers
• Claudin expression and prognosis in STAD